Neurocrine Biosciences, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| NBIX | ALKS | SUPN | AMLX | BCRX | AQST | |
|---|---|---|---|---|---|---|
| Market cap | 14.37B | 6.75B | 2.49B | 3.45B | 2.14B | 603.71M |
| P/E (TTM) | 20.6 | 105.9 | — | — | — | — |
| Forward P/E | 11.8 | 22.3 | 9.6 | -23.9 | 8.9 | -8.4 |
| Price/book | 3.9 | 3.7 | 2.4 | 12.8 | -4.7 | -10.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +3.02% | +26.05% | −13.02% | +93.66% | +30.22% | −30.09% |
| Today | −0.75% | −0.86% | +0.33% | −2.35% | −2.22% | +0.63% |
The closest companies by business and industry (Drug Manufacturers - Specialty & Generic). Prices may be delayed up to 15 min.
Latest news
All NBIX news ›Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2026 Financial Results
Oct 12, 2026, 16:01 ET Conference Call and Webcast Scheduled for Monday, November 2 SAN DIEGO, Oct. 12, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2026 financial…
Comparing Scilex (NASDAQ:SCLX) & Neurocrine Biosciences (NASDAQ:NBIX)
Posted by Defense World Staff on Oct 8th, 2026 Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) and Scilex (NASDAQ:SCLX – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two…
Neurocrine Biosciences CMO reports 51,331 shares
Neurocrine Biosciences (NBIX) is a neuroscience-focused biopharma company with FDA-approved treatments for tardive dyskinesia, Huntington’s chorea and adrenal disorders. - [Form 3] NEUROCRINE BIOSCIENCES INC Initial Statement of Beneficial…
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Posted by Mitch Edgeman on Oct 7th, 2026 Read Our Latest Stock Analysis on NBIX Shares of NASDAQ:NBIX opened at $145.51 on Friday. The firm has a market cap of $14.79 billion, a price-to-earnings ratio of 21.34, a P/E/G ratio of 0.67 and a…
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
Sep 30, 2026, 08:30 ET The research reflects Neurocrine's continued commitment to ongoing education of Prader-Willi syndrome (PWS) and VYKAT XR — the first and only FDA-approved treatment for hyperphagia in people aged 4 years and older…
Neurocrine Biosciences Welcomes Back Eiry Roberts as Chief Medical Officer
Why This Matters: See our coverage of other industry executive team appointments and promotions here. Neurocrine Biosciences named Eiry Roberts, MD, Chief Medical Officer, returning Roberts to a post she held from 2018 to 2025. Roberts had…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
stocktitan.net2
-
contractpharma.com1
-
defenseworld.net1
-
prnewswire.com1
-
themarketsdaily.com1
Finance and business coverage in the 4Conservative news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.